Pelthos Therapeutics Inc. (NYSE: PTHS)

Pelthos Therapeutics Inc. is a bio-pharmaceutical company dedicated to developing and commercializing innovative therapeutic products that address unmet medical needs. The firm currently markets 3 U. S. Food and Drug Administration approved products: ZELSUVMI for the treatment of molluscum contagiosum, XEPI for impetigo, and XEGLYZE for head lice. Beyond its commercial portfolio, Pelthos leverages its proprietary NITRICIL nitric oxide technology platform to enable new formulation opportunities and to support the manufacture of active pharmaceutical ingredients. The company also maintains a research pipeline focused on novel nonopioid pain therapies that target the NaV1.7 sodium channel, encompassing programs for eye pain, postoperative nerve block pain, and neuropathic pain conditions.

Pelthos generates revenue primarily from the sale of its FDA approved products ZELSUVMI, XEPI, and XEGLYZE through pharmaceutical distribution channels. The company also receives income from manufacturing services related to the NITRICIL platform under its master services agreement with Ligand Pharmaceuticals, which includes supplying active pharmaceutical ingredient for internal and external use. No other material revenue streams are disclosed in the filing.

The company operates through the following segments: Commercial Operations and Research and Development.

• Commercial Operations: This segment manages the sale, promotion, and distribution of approved products, including ZELSUVMI, XEPI, and XEGLYZE, and oversees marketing campaigns, pricing strategies, and relationships with national and regional wholesalers, retail pharmacy chains, independent pharmacies, and mail order providers.

• Research and Development: This segment conducts preclinical and clinical studies to advance NaV1.7-targeted pain programs, supports the NITRICIL technology platform for new formulation opportunities, oversees manufacturing process development for active pharmaceutical ingredients, and prepares regulatory submissions for investigational therapies.

Pelthos holds a differentiated position in the dermatology market as the 1st and only FDA approved prescription therapy for molluscum contagiosum that can be administered outside a clinical setting. Its NITRICIL platform provides a novel mechanism of action using nitric oxide, which offers potential advantages over existing therapies such as cryotherapy, cantharidin, and off label compounds. The company addresses a substantial unmet need, with management estimating that approximately 16 million people in the United States suffer from molluscum contagiosum each year. Competitors include topical antibiotics, procedural treatments, and emerging biologics, but Pelthos's proprietary technology and focused pipeline aim to create sustainable barriers to entry.

The company sells its products to national and regional wholesalers, which in turn supply retail drug store chains, independent pharmacies, and mail order pharmacies. Prescribers include pediatricians, dermatologists, and infectious disease specialists who recommend the therapies to patients and caregivers. Patient populations served encompass children, immunocompromised individuals, and sexually active adults affected by the targeted skin infections.